Activated lymphocytes from breast cancer patients express the characteristics of type 2 helper cells - A possible role for breast cancer-associated p43

Cancer Letters

Volumn 127, Issue 1-2, 1998, Pages 129-134

  Rosen, Harald R ^a   Ausch, Christoph ^a   Reinerova, Marta ^b   Zaspin, Eleonora ^c   Renner, Karl ^a   Rosen, Alexander C ^a   Schiessel, Rudolf ^a   Moroz, Chaya ^c  

^a Ludwig Boltzmann Res Inst Surg O   (Austria)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Breast cancer; Cytokines; Immune response; Immune suppression; Lymphocytes; p43

Indexed keywords

ANTIGEN; CONCANAVALIN A; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MITOGENIC AGENT; PROTEIN P43; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST DISEASE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; HELPER CELL; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CONCANAVALIN A; CYTOKINES; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; PEPTIDE ELONGATION FACTOR TU; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0032523975     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00017-2     Document Type: Article

References (24)

1. + effector T cells. J. Exp. Med. 159:1984;1295-1311.
2. Bursoker I., North R.J. Generation and decay of the immune response to progressive fibrosarcoma I. Failure to demonstrate postexcision immunity after the onset of T cell mediated suppression of immunity. J. Exp. Med. 159:1984;1312-1321.
3. Moroz C., Giler S., Kupfer B., Urca J. Lymphocyte bearing surface ferritin in patients with Hodgkin's disease and breast cancer. N. Engl. J. Med. 296:1977;1173-1176.
4. Moroz C., Shterman N., Kupfer B. T-Cell mitogenesis stimulates the appearance of a new mRNA species coding for a 43kD peptide reactive with CM-H-9 monoclonal antibody specific for placental isoferritin. Proc. Natl. Acad. Sci. USA. 86:1989;3282.
5. Maymon R., Bahary C., Moroz C. Placental isoferritin: a new serum marker in toxemia of pregnancy. Am. J. Obstet. Gynecol. 160:1989;681-684.
6. Rosen A.C., Rosen H.R., Huber K., Bauer K., Ausch C., Redlich K., Klein M.J., Moroz C. Correlation of placental isoferritin with birth weight and time point of first contractions. Gynecol. Obstet. Invest. 39:1995;11-14.
7. Rosen H.R., Ausch C., Reiner G., Reinerova M., Svec J., Tüchler H., Moroz C. Downregulation of lymphocyte mitogenesis by breast cancer associated p43. Cancer Lett. 82:1994;105-111.
8. Rosen H.R., Ausch C., Reiner G., Reinerova M., Svec J., Tüchler H., Schiessel R., Moroz C. Immunosuppression by breast cancer associated p43 - effect of immuno-modulators. Breast Cancer Res. Treat. 41:1996;171-176.
9. Clerici M., Shearer G.M. The TYPE 1-TYPE 2 hypothesis of HIV infection. New insights. Immunol. Today. 15:1994;575-581.
10. Montaner L.J., Doyle A.G., Collin M. Interleukin 13 inhibits human immunodeficiency virus type I production in primary blood derived human macrophages in-vitro. J. Exp. Med. 178:1993;743-747.
11. Zurawski G., De-Vries J.E. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells but not on T cells. Immunol. Today. 15:1994;19-26.
12. Bloom H.J.G., Richardson W.W. Histologic grading and prognosis in breast cancer. Br. J. Cancer. 11:1957;359-364.
13. Stierer M., Rosen H., Weber R., Hanak H., Spona J., Tüchler H. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Ann. Surg. 218:1993;13-21.
14. Del Prete G.M., De Carli F., Almerigogna M.G., Giudici R., Biagiotti M., Romagnani S. Human IL-10 is produced by both type I helper T clones and type 2 helper T clones and inhibits their antigen specific proliferation and cytokine production. J. Immunol. 150:1993;353-360.
15. Salgame P., Abrams J.S., Clayberger C., Goldstein H., Convit J., Modlin R.L., Bloom B.R. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science. 254:1991;279-282.
16. Yamamura M., Uyemura K., Deans R.J., Weinberg K., Rea T.H., Bloom B.R., Modlin R.L. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science. 254:1991;277-279.
17. + T cell clones isolated from human renal cell carcinoma possess a functional characteristics Th2 helper cells. Cell. Immunol. 150:1993;114-123.
18. Rosen H.R., Stierer M., Göttlicher J., Wolf H., Spoula H., Eibl M. Determination of placental ferritin-positive peripheral lymphocytes in early stages of breast cancer. Am. J. Surg. 165:1993;213-217.
19. Sedlak J., Reinerova M., Hunakova L., Ausch C., Chorvath B., Rosen H., Moroz C. Alterations of cell surface antigens induced by placental isoform of ferritin in human carcinoma cell lines. Cancer Lett. 94:1995;101-106.
20. Swain S.L., Weinberg A.D., English M., Huston G. IL-4 directs the development of TYPE 2 like helper effectors. J. Immunol. 145:1990;3796-3802.
21. + T cells from T cell receptor transgenic mice. J. Exp. Med. 176:1992;1091-1098.
22. - cells that make TYPE 2 cytokines and help B cells. Science. 260:1993;1802-1805.
23. + T cells. Their activation and effector function. Curr. Opin. Immunol. 6:1994;453-457.
24. Moroz C., Misrock S.L., Siegal F. Isoferritin in HIV infection: relation to clinical stage, CD8 lymphocyte binding and the pathogenesis of AIDS. AIDS. 3:1989;11-16.